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Summary-Dexamethasone, a synthetic glucocorticoid, decreases the plasminogen activator (PA) activity 
of HTC rat hepatoma cells in tissue culture. Paradoxically, dexamethasone enhances the cyclic nucleotide 
stimulation of PA activity in these cells 24-fold. In this report, we investigated whether this paradoxical 
glucocorticoid effect is mediated by the same proximal events which mediate such direct regulatory actions 
of glucocorticoids as the induction of tyrosine aminotransferase activity. We compared the concentration- 
dependences for several classes of steroids, previously classified as full agonists, partial agonists, 
antagonists or inactive steroids with respect to induction of the transaminase, for both enhancement of 
cyclic nucleotide stimulation of PA activity and induction of tyrosine aminotransferase activity in parallel 
cultures. The full agonists dexamethasone and cortisol, the partial agonists deoxycorticosterone and 
1 Ifi-hydroxyprogesterone, the inactive steroid tetrahydrocortisol, and the antagonist I ‘la-methyl- 
testosterone exhibited similar potencies with respect to both phenomena. Furthermore, when cells were 
incubated with both dexamethasone and 17a-methyltestosterone, the latter blocked enhancement by 
dexamethasone in a concentration-dependent fashion. We conclude that glucocorticoid enhancement of 
cyclic nucleotide stimulation of PA activity is mediated by the same glucocorticoid receptors which 
mediate direct regulatory effects. 
INTRODUCTION 
Dexamethasone, a synthetic glucocorticoid, dra- 
matically decreases the plasminogen activator (PA) 
activity of rat hepatoma tissue culture (HTC) cells 
through the induction of a specific inhibitor of 
PA [ 1,2]. In contrast, cyclic nucleotides stimulate 
both the cell-associated and extracellular activity of 
this serine protease. Paradoxically, dexamethasone 
enhances this stimulation 24-fold [3]. This latter 
glucocorticoid effect can be dissociated from the 
direct glucocorticoid regulatory action on PA: en- 
hancement of cyclic nucleotide stimulation by dex- 
amethasone is also observed in variant HTC cells 
which are selectively resistant to glucocorticoid in- 
hibition of PA activity [4]. 
Current models of steroid hormone action propose 
that steroids diffuse freely into cells and bind revers- 
ibly to specific cytoplasmic receptors. Following 
activation to a chromatin-binding form, the 
receptor-steroid complexes translocate to the nu- 
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cleus, and are thought to bind to specific sites on 
chromatin and mediate the metabolic effects of the 
steroid by transcriptional regulation of specific 
genes [5, 61. Evidence for this model includes the 
direct correlations which have been reported between 
cytoplasmic binding, nuclear binding, and induction 
of tyrosine aminotransferase (TAT) by several 
different classes of steroids in HTC cells [7, 81. If 
glucocorticoid enhancement of cyclic nucleotide stim- 
ulation of PA activity in HTC cells is mediated by the 
same proximal events that mediate the direct regu- 
latory effects of glucocorticoids (e.g. induction of 
TAT), the doseeresponse relationships for various 
steroids should be comparable. In other systems, 
however, the concentrations of dexamethasone re- 
quired to elicit permissive and interactive effects of 
glucocorticoids have varied widely [991 l] and the 
mechanisms of such interactions of glucocorticoids 
with other hormones and effecters remain to be 
identified [9, 121. 
In this study, we measured the dose-response 
relationships of several classes of steroids for en- 
hancement of cyclic nucleotide stimulation of PA 
activity and for induction of TAT activity in parallel 
cultures at 24 h, a time when both responses should 
be stable and maximal. Samuels and Tomkins [13] 
have previously classified steroids on the basis of their 
ability to induce TAT. Full agonists maximally in- 
duce the biological response; partial agonists, which 
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also bind to the glucocorticoid receptor, induce the 
response suboptimally even at high concentrations; 
antagonists bind to the receptor, but fail to elicit a 
biological response; and, inactive steroids neither 
bind to the receptor nor elicit a response. We report 
here that these steroids exhibit the same relative 
potencies in the induction of TAT activity and en- 
hancement of cyclic nucleotide stimulation of PA 
activity. Furthermore, the antagonist 17u -methyl- 
testosterone blocks the enhancement by the agonist 
dexamethasone in a concentration-dependent man- 
ner. We conclude that the enhancement phenomenon 
is mediated by the same glucocorticoid receptors 
which mediate the direct actions of glucocorticoids. 
MATERIALS AND METHODS 
materials 
Eagle’s Minimal Essential Medium, calf and fetal 
bovine sera, glutamine, trypsin and neomycin were 
obtained from GIBCO Laboratories, Grand 
Island, New York. Dexamethasone (9x-fluoro- 
16x-methyl-l 1~,17~,21-trihydroxy-1 ,Cpregnadiene- 
3,20-dione) was a gift from Dr Walter Gall of Merck 
& Co. Cortisol (11&17a,21-trihydroxy-4-pregnene- 
3,20-dione), deoxycorticosterone(21-hydroxy-Cpreg- 
nene-3,20-dione), 1 lj?-hydroxyprogesterone (1 lp- 
hydroxy-4-pregnene-3,20-dione), tetrahydrocortisol 
(3x, 11~,17a,21- tetrahydroxy- SP-pregnan -20-one), 
and 17a - methyltestosterone (17~ - methyl - 178 - 
hydroxy-4-androsten-3-one) were purchased from 
Steraloids Inc., Wilton, New Hampshire and were 
each reported to migrate as a single spot on thin layer 
chromatography. Fibrinogen (98% clottable), 
8-bromadenosine-3’: S-cyclic monophosphoric acid 
and methylisobutylxanthine (MIBX) were obtained 
from Calb~ochem-Boeh~ng, San Diego, California. 
‘251-labeled fibrinogen (sp. act. - 150 mCi/g protein) 
was purchased from Amersham, Arlington Heights, 
Illinois. Plasminogen was purified from outdated 
human plasma by affinity chromatography [14]. All 
other compounds were of at least reagent grade. 
Cell culture 
HTC cells were grown in monolayer culture with- 
out antibiotics in Eagle’s Minimal Essential Medium 
supplemented with 50 mM tricine (N-[Zhydroxy-I, I- 
bis(hydroxymethyl)ethyl]glycine), 0.5 g/l sodium bi- 
carbonate, 2 mM glutamine, 0.02% caicium chloride, 
5% calf serum and 5% fetal bovine serum. 
Enzyme assays 
Tyrosine aminotransferase (L-tyrosine: 2-0x0- 
glutarate aminotransferase, EC 2.6.1 S) activity was 
measured as previously described by Spencer and 
Gelehrter 1151. Plasminogen activator activity in cell 
extracts (in 0.2% Triton X-100) and in medium 
conditioned by the cells was determined by the 
plasminogen-dependent solubilization of ‘251-labeled 
fibrin coated on multiwell plates as described 
elsewhere [l, 161. Solubilized radioactivity was cor- 
rected for background release and then expressed as 
a percentage of the total radioactivity solubilized by 
5O+ug trypsin. The various steroids, 8-Br-CAMP, 
MIBX, ethanol, and dimethyl sulfoxide did not alter 
either fibrinolytic activity or background release 
when added directly to the assay. 
Clucocorticoid treatment of cells 
Cells were plated at 1 to 2 x lOh cells/35 mm tissue 
culture dish in serum-supplemented medium. After 
the cells had grown to SO-900/, confluence, the mono- 
layers were washed twice with serum-free medium 
and then incubated for 24 h at 37°C in serum-free 
medium containing O.lo/:, bovine serum albumin, 
0.02% calcium chloride, 50 pg/ml neomycin and 
8-Br-CAMP, MIBX and various steroids at the con- 
centrations described in the Figure legends. Maximal 
stimulation of PA activity by cyclic nucleotides in 
HTC cells is observed when cells are incubated with 
the CAMP derivative 8-Br-CAMP and the potent 
phosphodiesterase inhibitor MIBX [3]. The maximal 
concentrations of ethanol (I. 1%) and dimethyl sulf- 
oxide (O.Sy$ used did not affect either the basal or 
induced levels of TAT or PA activity. 
RESULTS 
Concentration de~ende~~ce ofdexamethaso~e ~~duct~o~ 
of TAT activity, i#h~bit~on of PA activity. and en- 
hancement of 8-Br-cAMP stimulation of PA activity. 
Initially, we examined the dose-response re- 
lationships for dexamethasone induction of TAT 
activity, inhibition of PA activity, and enhancement 
of cyclic nucleotide stimulation of PA activity. In- 
hibition of PA activity and induction of TAT activity 
were measured in the same cultures, as described in 
Materials and Methods; the enhancement phenom- 
enon was examined in parallel cultures which con- 
tained 8-Br-CAMP and MIBX as well as dexa- 
methasone. In this experiment, the concentration- 
dependence upon dexamethasone is virtually identi- 
cal for all three phenomena (Fig. 1). Half-maximal 
response was obtained at 4 nM dexamethasone, and 
maximal response at approx 20nM. 
Steroid specificity oj’ the induction of TA T activity and 
enha~eement of cyclic ~~cieotide st~mMiat~on qf PA 
activity 
We measured the concentration-dependence of 
steroidal induction of TAT activity and enhancement 
of cyclic nucleotide stimulation of PA activity in 
parallel cultures after 24 h of incubation, a time when 
both effects should be stable and maxima1 (Fig. 2). As 
previously reported by Samuels and Tomkins 1131 
and by Gelehrter and McDonald [ 171, dex- 
amethasone and cortisol maximally induced TAT 
activity. Half-maximal induction was observed at 4 
and 50 nM, respectively. Deoxycorticosterone and 
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Fig. 1. Concentration-dependence of dexamethasone in- 
duction of TAT activity, inhibition of PA activity, and 
enhancement of 8-Br-CAMP stimulation of PA activity. 
Parallel cultures of HTC cells were incubated for 24 h in 
serum-free medium with increasing concentrations of dex- 
amethasone in the absence (A induction of TAT activity: 0 
inhibition of PA activity) or presence (0 enhancement of 
8-Br-CAMP stimulation of PA activity) of 3 mM 
8-Br-CAMP and 1 mM MIBX. Ethanol concentration was 
0.2x, and dimethyl sulfoxide concentration 0.5%. PA activ- 
ity and TAT activity were measured as previously described; 
results are expressed as a percentage of the maximal re- 
sponse. Maximal induction was 5-fold, maximal inhibition 
was 87%, and maximal enhancement was 2-fold. 
1 la-hydroxyprogesterone submaximally induced 
TAT activity. Deoxycorticosterone induced TAT to 
slightly higher levels than did 1 I/?-hydroxy- 
progesterone and was effective at lower concen- 
trations. Neither the antagonist, 17a-methyltesto- 
sterone, nor the inactive steroid, tetrahydrocortisol, 
induced TAT activity. 
Similar, although not identical, concentration- 
dependences were obtained for the enhancement 
phenomenon (Fig. 2B). The full agonists, dexa- 
methasone and cortisol, elicited maximal enhance- 
ment at the same relative potencies observed for the 
induction of TAT activity. Deoxycorticosterone and 
1 l/j’-hydroxyprogesterone again behaved as partial 
agonists, enhancing cyclic nucleotide stimulation of 
PA activity to 50 to 60% of the maximal response. 
However, the concentrations required for half- 
maximal enhancement by both full and partial 
agonists were somewhat lower than those required 
for half-maximal induction of TAT. Neither the 
antagonist nor the inactive steroid caused any en- 
hancement of cyclic nucleotide stimulation. 
Competitive interactions between steroids 
Antagonists block the induction of TAT and the 
inhibition of amino acid transport by full agonists, 
presumably by competing for binding to the glu- 
cocorticoid receptor [13, 171. If enhancement is in- 
deed mediated by glucocorticoid receptors, then the 
addition of 17a-methyltestosterone or progesterone 
should similarly block dexamethasone enhancement 
of stimulation of PA activity by CAMP derivatives. 
As illustrated in Fig. 3, 17cr-methyltestosterone does 
block the enhancement response elicited by dexa- 
methasone in a concentration-dependent fashion. In 
the absence of dexamethasone, these concentrations 
of 17c(-methyltestosterone have no effect on PA 
activity. Progesterone similarly blocks dex- 
amethasone enhancement; However, at high concen- 
trations ( 9 10 PM) in the absence of dexamethasone, 
progesterone itself enhances CAMP effects (data not 
shown). Similar anomalous effects of high concen- 
trations of progesterone were observed on inhibition 
of amino acid transport in HTC cells [17]. 
DISCUSSION 
The concentration-dependence of the dexa- 
methasone induction of tyrosine aminotransferase 
activity is directly correlated with the binding of 
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Fig. 2. Steroid specificity of the induction of TAT activity 
and of the enhancement of 8-Br-CAMP stimulation of PA 
activity. HTC cells were incubated for 24 h in serum-free 
medium in the absence (TAT samples) or presence (PA 
samples) of 3mM 8-Br-CAMP and 1 mM MIBX with 
increasing concentrations of: (0) dexamethasone, (0) cor- 
tisol, (0) deoxycorticosterone, ( n ) 11 fi-hydroxy- 
progesterone, (+) 17a-methyltestosterone, or (0) tet- 
rahydrocortisol; TAT activity (Fig. 2A) and both cell- 
associated and extracellular PA activity (Fig. 2B) were 
measured in duplicate assays of single (TAT) or duplicate 
(PA) cultures. Results are expressed as the percentage 
(mean f SEM) of the maximal response observed in 
dexamethasone-treated cultures. Data are derived from at 
least three experiments at each concentration for all the 
steroids tested except 17u-methyltestosterone and tet- 
rahydrocortisol; those data are from two experiments. Max- 
imal induction of TAT was 8.8 f 0.2-fold (mean + SEM) 
and maximal enhancement of PA was 3.9 + l.O-fold. 
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Fig. 3. Enhancement of 8-Br-CAMP stimulation of PA 
activity by dexamethasone: competition by 17a-methyl- 
testosterone. HTC cells were incubated in serum-free me- 
dium containing I mM 8-Br-CAMP and 1 mM MIBX with 
increasing concentrations of: (0) dexamethasone; (4) 
17a-methyltestosterone; or, (0) 17z-methyltestosterone 
and a constant concentration (5 nM) of dexamethasone. 
Each point is derived from duplicate assays of a single 
culture and is expressed as a percentage of the maximal 
enhancement observed in dexamethasone-treated cultures. 
Maximal enhancement was 2-g-fold. 
dexamethasone to cytoplasmic receptors, and with 
the nuclear binding of receptor-steroid complexes in 
HTC cells [S-S]. Furthermore, the concentration- 
dependences for the dexamethasone induction of 
tyrosine aminotransferase, alkaline phos- 
phodiesterase I and cell adhesiveness, and the in- 
hibition of amino acid transport and plasm~nogen 
activator activity are virtually identical (Fig. 1 and 
Ref. 5-8, 17-2 1) consistent with these phenomena all 
being mediated by the same glucocorticoid receptors. 
Additional support for this view comes from studies 
of the steroid specificity of these effects using various 
classes of steroids including full agonists, partial 
agonists, antagonists and inactive 
steroids [ 13, 17,2 11. Similar observations have been 
made for direct glucocorticoid effects in other experi- 
mental systems [22]. 
In contrast, the dose-response relationships for 
permissive or interactive effects of glucocorticoids 
with other hormones and effecters vary considerably. 
The concentration-dependence of the permissive 
effect of dexamethasone on dibutyryl CAMP in- 
duction of TAT in HTC cells is right-shifted relative 
to the concentration~e~ndence for direct giu- 
cocorticoid induction of TAT in these cells [9]. How- 
ever, glucocorticoid inhibition of vasoactive intestinal 
peptide stimulation of CAMP accumulation and pro- 
lactin secretion in cultured rat pituitary cells occurs 
at picomolar concentrations and is glucocorticoid- 
specific [ 111. 
In HTC cells, dexamethasone both inhibits PA 
activity and, paradoxically, enhances the stimulation 
of PA activity by cyclic nucfeotides. In this report, 
we have presented two lines of evidence that this 
paradoxical steroidal effect on cyclic nucleotide regu- 
lation of PA activity is mediated by glucocorticoid 
receptors. First, several classes of steroids exhibit 
similar potencies with respect to both induction of 
TAT and enhancement of cyclic nucleotide stimu- 
lation of PA. Second, the antagonist 17a-methyl- 
testosterone blocks the enhancement by dex- 
amethasone in a concentration-dependent manner. 
Although our data suggest that the paradoxical 
effects of dexamethasone on PA activity are mediated 
by glucocorticoid receptors, it should be noted that 
the enhancement of cyclic nucleotide stimulation of 
PA activity occurs at slightly lower concentrations of 
dexamethasone than does the induction of trans- 
aminase activity (Figs 2 and 3). A similar leftward 
shift in concentration-dependence is also noted 
for cortisol and for the partial agonists 
deoxycorticosterone and I Ifi-hydroxyprogesterone 
(Fig. 2). Mercier et a/.[23] have reported a similar, 
though even more striking, leftward shift in the 
concentration-dependence for a dexamethasone- 
induced biological effect relative to binding of dex- 
amethasone to glucocorticoid receptors. In FUS-5 rat 
hepatoma cells, the dose-response curve for dex- 
amethasone induction of tyrosine aminotransferase is 
shifted to the left approx. 7-fold relative to that for 
dexamethasone binding to whole cells, and to that for 
induction of glutamine synthetase. The explanation 
for such discrepant dose-response relationships is not 
known, but the occurrence of such non-linear re- 
lationships between the concentration-dependence 
for glucocorticoid binding and biological action sug- 
gests greater complexity than that included in current 
models of glucocorticoid action [5,6, 8,221. 
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